Desipramine

Desipramine is a tricyclic psychotic compound, possessing antidepressant activity. Desipramine inhibits the norepinephrine reuptake receptor in the central nervous system and reduces the sleep-related loss of genioglossus activity, can be used to research the improvement of pharyngeal collapsibility[1][2].

Product Specifications

CAS Number

[50-47-5]

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/desipramine.html

Solubility

10 mM in DMSO

Smiles

CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31

Molecular Formula

C18H22N2

Molecular Weight

266.38

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Garcia AS, et al. Autoreceptor-mediated inhibition of norepinephrine release in rat medial prefrontal cortex is maintained after chronic desipramine treatment. J Neurochem. 2004 Nov;91 (3) :683-93.|[2]Taranto-Montemurro L, et al. Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation. Eur Respir J. 2016 Nov;48 (5) :1340-1350.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Research Square Print. 2023 Feb 23.|Biochim Biophys Acta Mol Basis Dis. 2023 Mar 28;1869 (5) :166700.|Br J Pharmacol. 2024 Dec;181 (23) :4874-4889.|Cell. 2025 Oct 24:S0092-8674 (25) 01131-6.|Glia. 2022 Nov;70 (11) :2093-2107.|Inflammation. 2021 Aug;44 (4) :1592-1606.|J Parkinson Dis. 2020;10 (2) :523-542.|Neural Regen Res. 2021 Aug;16 (8) :1660-1670.|Neuroscience. 2024 Mar 26:542:11-20.|Neurotoxicology. 2022 Dec:93:173-185.|Parkinsons Dis. 2022 Nov 14:2022:1428817.|Pharmaceutics. 2022 Jul 22;14 (8) :1523.|Sci Total Environ. 2024 May 1:923:171405.